Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial
Marc Ychou, Michel Rivoire, Simon Thezenas, Rosine Guimbaud, Francois Ghiringhelli, Anne Mercier-Blas, Laurent Mineur, Eric Francois, Faiza Khemissa, Marion Chauvenet, Reza Kianmanesh, Marianne Fonck, Philippe Houyau, Thomas Aparicio, Marie-Pierre Galais, Franck Audemar, Eric Assenat, Evelyne Lopez-Crapez, Claire Jouffroy, Antoine Adenis, René Adam, Olivier Bouché
Topics & Concepts
MedicineCetuximabBevacizumabInternal medicineOncologyTargeted therapyColorectal cancerClinical trialChemotherapyRadiation therapyRandomizationRandomized controlled trialCancerOverall survivalSurgeryColonic diseaseNeoadjuvant therapyHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesCancer Research and Treatments